Gain Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Gain Therapeutics Depreciation & Amortization Growth & History (GANX)
Gain Therapeutics's depreciation and amortization was $94,046 for fiscal 2025.
View full Gain Therapeutics company overviewGain Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $94,046 | $9,975 | +11.86% |
| 2024 | 2024-12-31 | $84,071 | $492 | +0.59% |
| 2023 | 2023-12-31 | $83,579 | $19,411 | +30.25% |
| 2022 | 2022-12-31 | $64,168 | $48,684 | +314.41% |
| 2021 | 2021-12-31 | $15,484 | $5,892 | +61.43% |
| 2020 | 2020-12-31 | $9,592 | — | — |
Gain Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $27,170 | $4,842 | +21.69% |
| Q1 2026 | 2026-03-31 | $21,303 | $643 | +3.11% |
| Q4 2025 | 2025-12-31 | $28,241 | — | — |
| Q3 2025 | 2025-09-30 | $22,817 | $1,174 | +5.42% |
| Q2 2025 | 2025-06-30 | $22,328 | $1,735 | +8.43% |
| Q1 2025 | 2025-03-31 | $20,660 | $132 | +0.64% |
| Q3 2024 | 2024-09-30 | $21,643 | $1,134 | +5.53% |
| Q2 2024 | 2024-06-30 | $20,593 | $354 | +1.75% |
| Q1 2024 | 2024-03-31 | $20,528 | $1,286 | +6.68% |
| Q3 2023 | 2023-09-30 | $20,509 | $2,681 | +15.04% |
| Q2 2023 | 2023-06-30 | $20,239 | $218 | +1.09% |
| Q1 2023 | 2023-03-31 | $19,242 | $11,033 | +134.40% |
| Q3 2022 | 2022-09-30 | $17,828 | $13,693 | +331.15% |
| Q2 2022 | 2022-06-30 | $20,021 | $17,863 | +827.76% |
| Q1 2022 | 2022-03-31 | $8,209 | $4,806 | +141.23% |
| Q3 2021 | 2021-09-30 | $4,135 | $1,754 | +73.67% |
| Q2 2021 | 2021-06-30 | $2,158 | −$118 | −5.18% |
| Q1 2021 | 2021-03-31 | $3,403 | $1,302 | +61.97% |
| Q3 2020 | 2020-09-30 | $2,381 | — | — |
| Q2 2020 | 2020-06-30 | $2,276 | — | — |
| Q1 2020 | 2020-03-31 | $2,101 | — | — |
Gain Therapeutics depreciation and amortization trends
Over the last five fiscal years, Gain Therapeutics's depreciation and amortization increased from $9,592 to $94,046, a change of $84,454. The latest reported quarter, Q2 2026, shows $27,170.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gain Therapeutics source filings ↗